TY - T1的灰质体积减少焦相比特发性全身性癫痫(P7.003) JF -神经学乔-神经学六世- 84 - 14补充SP - P7.003盟莫妮卡Dhakar AU -保分盟丽娜Pullukat AU -迈克尔Aronov首页 AU -林赛·米勒盟茉莉花Bhangu AU -卡拉圣地亚哥马丁内斯盟Deepti Zutshi AU - Maysaa岜沙非盟- Aashit Shah盟奥马尔汗Y1 - 2015/04/06 UR - //www.ez-admanager.com/content/84/14_Supplement/P7.003.abstract N2 -目的:检查规范化成人特发性全身性癫痫患者脑容量(IGE)和局部癫痫。背景:癫痫和脑容量之间的关系还不清楚。很少有研究标准化的脑容量(NBV),灰质体积(NGMV),胼胝体白质(NGWV), (CC)区域不同的癫痫患者表型。方法:成人癫痫患者是在我们综合癫痫中心被包括在内。患者分为三组。组1:局灶性癫痫没有二级泛化(n = 10);组2:局灶性癫痫与二级泛化(n = 16);第三组:IGE (n = 10)。年龄、性别、癫痫、持续时间、发作频率记录。在1.5 t MRI扫描得到扫描仪。 NBV, NGMV and NWMV were quantified using fully automated SIENAX v2.6 software. CC area was estimated with a semi-automated technique using JavaIMv6. RESULTS: Patients in Group 1 were older than in Group 3 (51.3±18.1 vs 34.3±10.2 years, p=0.03). Duration of epilepsy and seizure frequency were similar among all three groups. There were no significant differences in NBV, NBWV, and CC area across the three groups. Lower NGMV was seen in Group 1 compared to group 3 (715.94 ml vs 757.61ml, p=0.045) and in Group 2 compared to Group 3 (686.91 vs 757.61 ml, p=0.02). Furthermore, NGMV in focal onset epilepsy Groups 1 and 2 (698 ml) was significantly lower than the IGE Group 3 (698 vs 757.6 ml, p=0.011)). There was no significant difference in the NGMV between Groups 1 and 2. CONCLUSIONS: Patients with focal onset epilepsy have significantly reduced NGMV compared to IGE. These observations may be related to the underlying pathophysiology of focal versus IGE. Our findings warrant larger prospective studies examining regional and deep GM volume as well cognition and quality of life that may be impaired due to reduced gray matter.Disclosure: Dr. Dhakar has nothing to disclose. Dr. Bao has nothing to disclose. Dr. Pullukat has nothing to disclose. Dr. Aronov has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Bhangu has nothing to disclose. Dr. Santiago Martinez has nothing to disclose. Dr. Zutshi has nothing to disclose. Dr. Basha has nothing to disclose. Dr. Shah has received personal compensation for activities with UCB Pharma as a consultant. Dr. Khan has received personal compensation for activities with Biogen Idec, Genzyme, Novartis, and Teva Neuroscience. Dr. Khan has received research funding from National Institutes of Health, National Institute of Neurological Disorders and Stroke, NatiThursday, April 23 2015, 2:00 pm-6:30 pm ER -